Eculizumab Kidney Protection: Shielding Children from Food Poisoning Effects
British medical pioneers have introduced Eculizumab Kidney Protection, a promising drug therapy. That defends children from the severe kidney damage frequently triggered by food poisoning.
This groundbreaking discovery reveals that Eculizumab. Which has already approved by the NHS for a genetic blood disorder has the potential to eliminate the need, for dialysis, transplants. And even save lives of affected children.
The primary culprit behind kidney failure in children is an infection called Shiga toxin producing E. Coli (STEC). This bacterial infection is typically contract through food.
The severity of this infection can vary from pain to severe symptoms such as bloody diarrhea and vomiting. In 10% of cases STEC enters the bloodstream through the system causing damage. To blood vessels and clotting in the kidneys. This condition is known as syndrome (STEC HUS).
The Harrowing Reality of STEC-HUS
This situation is especially devastating, for kids. It’s incredibly distressing that 5% of children below the age of ten who experience it either have to deal with kidney failure. For the rest of their lives or sadly lose their lives.
A comprehensive research study, funded by the Medical Research Council and Kidney Research UK and conducted by the University of Bristol has shed light on how the Shiga toxin affects the kidneys.
It specifically attacks a type of cells called podocytes. Lab tests have shown that Eculizumab Kidney Protection effectively stops this harmful process.
Currently the drug known as Soliris is used primarily to treat hemoglobinuria. A genetic condition in which the immune system mistakenly attacks red blood cells that are vital, for kidney function.
Richard Coward, a professor specializing in medicine at the University of Bristol emphasized the seriousness of STEC HUS in the field of pediatric medicine.
He stated that STEC HUS is one of the diseases face by medical professionals. And can result in kidney failure and even death. Our research has identified the podocyte as a target, for the Shiga toxin. Thankfully, with Eculizumab Kidney Protection, it can be treat.”
Dr. Aisling McMahon, from Kidney Research UK emphasize that the study indicates that STEC HUS can be stop using a medication that is already being use in practice.
The next steps involve determining the ideal timing for Eculizumab Kidney Protection in STEC-HUC cases and launching trials for at-risk children.
